Written by: Puja H NambiarTao LiangNazzarena LaboJonathan HandEmily A BlumbergMeenakshi M RanaSander FlormanBrandy HaydelMichele I MorrisJoanna SchaenmanMoreno M S RodriguesWilliam A WerbelMary G BowringRachel J Friedman-MoracoPeter StockValentina StosorShikha MehtaAlexander J GilbertNahel EliasSapna A MehtaCatherine B SmallGhady HaidarMaricar MalinisMarcus R PereiraSaima AslamDavid WojciechowskiRicardo La HozCarlos A Q SantosSenu ApewokinJose A Castillo-LugoKarthik RangannaMegan MorsheimerAllan MassieDorry L SegevWendell MileyVickie MarshallDenise WhitbyAaron A A TobianChristine M Durand
Find these authors on Roon
JH
Dr. Jonathan Hand
Transplant/Immunocompromised States · Ochsner Health
JS
Dr. Joanna Schaenman
Transplant/Immunocompromised States · UCLA
SM
Dr. Sapna A. Mehta
Transplant/Immunocompromised States · NYU Langone
Summary
BACKGROUND: Due to high prevalence of Kaposi sarcoma-associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+).METHODS: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D-) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD.RESULTS: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D-. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07-2.14] in recipients and 2.39 [95% CI, 1.03-5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D-/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26-1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D-/R+ and were likely recipient KSHV reactivation or acquisition.CONCLUSIONS: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.
JS
Dr. Joanna Schaenman
Infectious Disease · Transplant/Immunocompromised StatesUniversity of California, Los AngelesjoannasLos Angeles, CA, USA